Finanzen von Immunome Inc (IMNM)IMNMImmunome Inc

Evaluating the bottom line, Immunome, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.03%, provide a clear picture of how effectively IMNM converts its operational activities into shareholder value.

In the context of the broader market, IMNM competes directly with industry leaders such as ALMR and PHVS. With a market capitalization of $2.11B, it holds a significant position in the sector. When comparing efficiency, IMNM's gross margin of N/A stands against ALMR's 60.21% and PHVS's N/A. Such benchmarking helps identify whether Immunome, Inc. is trading at a premium or discount relative to its financial performance.

Immunome has shown fluctuating revenue with a total revenue of $4.015 million in Q2 2025, but has faced significant net losses, including -$43.4 million in Q2 2025. The gross margin has been 100% in recent quarters, indicating strong product profitability when revenues are generated.